KO · Coca-Cola
7.1% of portfolio
Consumer Staples · $382B
Sells concentrate to a worldwide bottling system, so it earns high margins on something people buy every day in nearly every country, and it has raised its dividend every year for more than six decades. Its sales barely move with the economy, which is why the stock trades like a bond with a brand attached.
Risk. You pay a premium for that steadiness, about 25 times next year's earnings, and volume growth is slow. A strong dollar or a lasting shift away from sugary drinks shows up straight in the results.
fwd P/E 25.4 · FCF yield 3.7% · revenue growth 3y +4% · expected EPS growth +5% · net debt/EBITDA 1.5
3y vol 17% · beta 0.03 · 12-mo trend +27% · 2022 -5% · 2020 -37% · score 70
JNJ · Johnson & Johnson
6.5% of portfolio
Health Care · $671B
With consumer health spun off, this is a pharmaceutical and medical-device company with one of the last AAA balance sheets, a pipeline in cancer and immunology that replaces what goes off patent, and a dividend raised for over sixty years.
Risk. Talc litigation has run for years and the final bill is still unknown, and its biggest drug, Stelara, is losing exclusivity to cheaper biosimilars.
fwd P/E 21.7 · FCF yield 3.3% · revenue growth 3y +6% · expected EPS growth +49% · net debt/EBITDA 0.8
3y vol 18% · beta 0.01 · 12-mo trend +44% · 2022 -3% · 2020 -25% · score 73
TJX · TJX Companies
6.3% of portfolio
Consumer Discretionary · $145B
TJ Maxx, Marshalls and HomeGoods buy excess stock from brands and sell it cheap. That works in good times and better in bad ones, when shoppers trade down and suppliers have more to unload. It has grown stores and same-store sales for decades with almost no debt.
Risk. It is priced as a winner, about 25 times next year's earnings, so a dip in store traffic or margin pressure from wages and freight would hit the share price harder than the business.
fwd P/E 25.1 · FCF yield 4.0% · revenue growth 3y +7% · expected EPS growth -2% · net debt/EBITDA 0.9
3y vol 18% · beta 0.42 · 12-mo trend +15% · 2022 -14% · 2020 -42% · score 59
CB · Chubb
6.2% of portfolio
Financials · $134B
The largest listed property and casualty insurer, with a long record of underwriting for profit rather than chasing premium growth, and an investment portfolio that now earns far more since bond yields rose. About 12 times next year's earnings.
Risk. One bad catastrophe year, hurricanes, wildfires or a major earthquake, can erase the underwriting profit, and softer pricing in commercial insurance would slow earnings growth.
fwd P/E 12.0 · FCF yield 11.4% · revenue growth 3y +12% · expected EPS growth +2% · net debt/EBITDA n/a
3y vol 19% · beta 0.14 · 12-mo trend +26% · 2022 -2% · 2020 -42% · score 72
CL · Colgate-Palmolive
6.0% of portfolio
Consumer Staples · $72B
People buy toothpaste whatever the economy does, and Colgate holds the largest share of it worldwide, plus pet food through Hill's, its fastest-growing business. Margins are high and cash generation is steady.
Risk. Growth is low single digits and the price is not cheap for it, about 22 times next year's earnings. Much of its money is earned in emerging-market currencies, which can swing reported results.
fwd P/E 22.0 · FCF yield 5.4% · revenue growth 3y +4% · expected EPS growth +61% · net debt/EBITDA 1.7
3y vol 20% · beta 0.04 · 12-mo trend +11% · 2022 -17% · 2020 -20% · score 70
EXC · Exelon
5.9% of portfolio
Utilities · $46B
A pure regulated utility since it spun off its power plants, delivering electricity and gas to about ten million customers around Chicago, Philadelphia, Baltimore and Washington. Regulators set its returns, so earnings grow with what it invests in the grid, and that investment is rising fast with electrification and data-centre demand.
Risk. It spends more than it earns to build that grid and borrows the difference, so it is sensitive to interest rates and to regulators refusing rate increases. Negative free cash flow is normal for a utility, but it means there is no cushion.
fwd P/E 14.6 · FCF yield -4.2% · revenue growth 3y +8% · expected EPS growth +12% · net debt/EBITDA n/a
3y vol 20% · beta 0.01 · 12-mo trend +5% · 2022 -10% · 2020 -40% · score 57
UNP · Union Pacific
5.5% of portfolio
Industrials · $172B
One of two railroads covering the western United States, a network nobody can build again, moving grain, chemicals, cars and containers with pricing power that has outrun inflation. It has proposed a merger with Norfolk Southern that would create the first coast-to-coast railroad.
Risk. Volumes track industrial production, so a recession cuts carloads quickly. Revenue has been flat for three years, and the merger could be blocked or come with costly conditions.
fwd P/E 20.4 · FCF yield 3.8% · revenue growth 3y -0% · expected EPS growth +15% · net debt/EBITDA 2.2
3y vol 21% · beta 0.58 · 12-mo trend +32% · 2022 -21% · 2020 -37% · score 67
MO · Altria
5.4% of portfolio
Consumer Staples · $116B
Cigarette volumes fall every year, and Altria still grows earnings by raising prices and buying back shares, then pays most of the cash out as a dividend that yields more than most bonds. At 12 times next year's earnings the market is pricing in the decline.
Risk. The decline can speed up, regulation is a standing threat (menthol bans, nicotine caps), and its attempts to buy growth outside cigarettes have destroyed capital before.
fwd P/E 12.0 · FCF yield 7.9% · revenue growth 3y -1% · expected EPS growth +22% · net debt/EBITDA 1.9
3y vol 22% · beta -0.05 · 12-mo trend +2% · 2022 -1% · 2020 -30% · score 78
SPG · Simon Property Group
5.1% of portfolio
Real Estate · $68B
Owns the best malls and premium outlets in the country. The weak malls have already closed, which has left Simon's occupancy and rents rising while almost nothing new is being built. It pays a large dividend from rent.
Risk. The most cyclical name on the calmer lists: it fell 63% in the 2020 crash and 39% in 2022, because malls depend on consumer spending and on credit markets, and like all REITs it carries substantial debt. Its forward P/E looks high because depreciation depresses REIT earnings; funds from operations is the better measure.
fwd P/E 31.7 · FCF yield 4.7% · revenue growth 3y +6% · expected EPS growth -53% · net debt/EBITDA n/a
3y vol 23% · beta 0.77 · 12-mo trend +22% · 2022 -39% · 2020 -63% · score 59
T · AT&T
5.1% of portfolio
Communication Services · $179B
Having sold its media businesses, it is a phone and fibre company again: adding wireless and fibre customers, paying down debt, and covering its dividend with cash to spare at about 10 times next year's earnings.
Risk. The turnaround has stalled before, price competition from cable and T-Mobile never stops, and the debt pile, though shrinking, is still large. The stock has lagged over the last year, so the market is not yet convinced.
fwd P/E 10.3 · FCF yield 9.8% · revenue growth 3y +1% · expected EPS growth -16% · net debt/EBITDA 2.7
3y vol 23% · beta -0.01 · 12-mo trend -20% · 2022 -18% · 2020 -30% · score 60
XOM · Exxon Mobil
5.0% of portfolio
Energy · $667B
The largest Western oil company, with low-cost barrels in Guyana and the Permian that keep it profitable at oil prices well below today's, very little net debt, and a dividend raised for decades.
Risk. Earnings follow the oil price, which nobody forecasts well, and 2020 showed what happens when demand disappears: the stock fell 48%. How long the world keeps needing more oil is the question the whole sector trades on.
fwd P/E 14.9 · FCF yield 4.6% · revenue growth 3y -7% · expected EPS growth +40% · net debt/EBITDA 0.4
3y vol 23% · beta 0.21 · 12-mo trend +38% · 2022 +60% · 2020 -48% · score 64
AON · Aon
5.0% of portfolio
Financials · $69B
An insurance broker, so it earns fees for placing risk rather than bearing it, and those fees rise with premiums and with the complexity of what clients need covered. It bought NFP to grow with mid-sized businesses and runs at high margins.
Risk. It carries meaningful debt from that deal, and the stock has gone nowhere for three years while rivals rose. It is on these lists for quality and price, not momentum, and the market may keep waiting.
fwd P/E 15.3 · FCF yield 4.7% · revenue growth 3y +11% · expected EPS growth +18% · net debt/EBITDA n/a
3y vol 24% · beta 0.24 · 12-mo trend -3% · 2022 -6% · 2020 -39% · score 63
PGR · Progressive
4.9% of portfolio
Financials · $127B
The most data-driven car insurer in the country, pricing risk with driving data and changing rates faster than rivals, which has let it add policies far faster than the industry while staying profitable. Revenue has compounded at about 20% a year for three years.
Risk. Car insurance is a cycle. When rates catch up with claims costs, competitors cut prices and growth slows, which is what the market has been pricing in: the stock has lagged over the last year.
fwd P/E 13.7 · FCF yield 12.5% · revenue growth 3y +21% · expected EPS growth -18% · net debt/EBITDA n/a
3y vol 24% · beta 0.11 · 12-mo trend -14% · 2022 +19% · 2020 -18% · score 63
LMT · Lockheed Martin
4.7% of portfolio
Industrials · $123B
The largest defence contractor, builder of the F-35, missiles and missile defence, with an order backlog measured in years and customers, governments, that keep paying in recessions. About 16 times next year's earnings, with a dividend.
Risk. Write-downs on fixed-price programmes have hit earnings before and can again. Defence budgets, and who wins the next big contract, are political decisions no model sees coming.
fwd P/E 16.2 · FCF yield 7.1% · revenue growth 3y +4% · expected EPS growth +22% · net debt/EBITDA 1.6
3y vol 25% · beta 0.13 · 12-mo trend +28% · 2022 +14% · 2020 -36% · score 72
AMGN · Amgen
4.5% of portfolio
Health Care · $240B
A large biotech with drugs for cholesterol, bone disease, cancer and inflammation, an obesity drug in late-stage trials, and rare-disease drugs from the Horizon acquisition. It generates large free cash flow and pays a growing dividend.
Risk. Patent expiries hit biotech hard and Amgen has several ahead. The obesity drug could fail or land in a crowded market, and it borrowed heavily to buy Horizon.
fwd P/E 18.2 · FCF yield 4.2% · revenue growth 3y +12% · expected EPS growth +52% · net debt/EBITDA 2.5
3y vol 26% · beta 0.51 · 12-mo trend +45% · 2022 +11% · 2020 -17% · score 73
MRK · Merck
4.5% of portfolio
Health Care · $376B
Keytruda, the world's best-selling cancer drug, carries the company, alongside a vaccine franchise and an animal-health business. Merck has been buying and licensing drugs to fill the gap when Keytruda's patents expire around 2028.
Risk. That expiry is the whole story. Keytruda is roughly half of drug sales, and if the replacements are late, earnings drop sharply. The stock has recovered strongly over the last year, which raises the bar.
fwd P/E 15.7 · FCF yield 4.3% · revenue growth 3y +3% · expected EPS growth +675% · net debt/EBITDA 3.3
3y vol 26% · beta 0.28 · 12-mo trend +53% · 2022 +21% · 2020 -18% · score 66
EOG · EOG Resources
4.3% of portfolio
Energy · $77B
The lowest-cost large shale producer in the United States, run to return cash rather than chase growth, with almost no net debt. It can pay its dividend at oil prices far below today's.
Risk. It is an oil price bet, full stop: it fell 55% in the 2020 crash. Revenue has shrunk for three years as oil came down from its 2022 highs.
fwd P/E 10.2 · FCF yield 8.6% · revenue growth 3y -9% · expected EPS growth +12% · net debt/EBITDA 0.2
3y vol 27% · beta 0.37 · 12-mo trend +12% · 2022 +43% · 2020 -55% · score 66
MPC · Marathon Petroleum
3.6% of portfolio
Energy · $109B
The largest U.S. refiner by capacity, with a pipeline business (MPLX) that pays it steady distributions, and a habit of buying back a large slice of its own shares every year. At about 12 times next year's earnings it is the cheapest energy name on the balanced list.
Risk. Refining margins swing violently with crude and fuel prices. It is the most volatile of the energy picks and fell 71% in the 2020 crash. It has also had the strongest run of them over the last year, so expectations are higher.
fwd P/E 11.8 · FCF yield 11.8% · revenue growth 3y -9% · expected EPS growth +14% · net debt/EBITDA 1.5
3y vol 33% · beta 0.63 · 12-mo trend +67% · 2022 +63% · 2020 -71% · score 71
NEM · Newmont
2.8% of portfolio
Materials · $137B
The world's largest gold miner, whose earnings rise with the gold price. It has sold its smaller mines to focus on its best ones and now holds more cash than debt. Gold has tended to hold up when stocks fall, and Newmont lost only 9% in the 2020 crash. The only name all three rules picked.
Risk. A gold price bet with mining risk on top: cost inflation, accidents, and politics in the countries where it digs. It fell 29% in 2022, when real interest rates rose and gold stalled.
fwd P/E 11.9 · FCF yield 7.1% · revenue growth 3y +24% · expected EPS growth +38% · net debt/EBITDA -0.2
3y vol 42% · beta 0.80 · 12-mo trend +41% · 2022 -29% · 2020 -10% · score 68
MU · Micron Technology
1.8% of portfolio
Information Technology · $1.08T
One of three companies in the world that make DRAM memory, and a leader in the high-bandwidth memory that AI accelerators need, which has turned a historically brutal commodity business into a boom and multiplied the stock over the last year. The balanced rule picked it for the technology sector on value, quality and momentum; it is the one name on that list outside the defensive theme.
Risk. Memory is the most cyclical business in technology. Prices collapse when supply catches up, and Micron has lost money in past downturns. It is the most volatile stock on the balanced list, about 64% a year with a beta above 2, it fell 45% in 2022, and its weight is held below 2% for exactly that reason.
fwd P/E 6.2 · FCF yield 2.4% · revenue growth 3y +7% · expected EPS growth +250% · net debt/EBITDA -0.3
3y vol 64% · beta 2.34 · 12-mo trend +610% · 2022 -45% · 2020 -36% · score 62